CL2022002398A1 - Compuestos para su uso en el tratamiento de la infección por coronavirus - Google Patents

Compuestos para su uso en el tratamiento de la infección por coronavirus

Info

Publication number
CL2022002398A1
CL2022002398A1 CL2022002398A CL2022002398A CL2022002398A1 CL 2022002398 A1 CL2022002398 A1 CL 2022002398A1 CL 2022002398 A CL2022002398 A CL 2022002398A CL 2022002398 A CL2022002398 A CL 2022002398A CL 2022002398 A1 CL2022002398 A1 CL 2022002398A1
Authority
CL
Chile
Prior art keywords
treatment
compounds
coronavirus infection
coronavirus
infection
Prior art date
Application number
CL2022002398A
Other languages
English (en)
Inventor
Avilés Marín Pablo
Losada González Alejandro
María Fernández Sousa-Faro José
Fudio Muñoz Salvador
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of CL2022002398A1 publication Critical patent/CL2022002398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto de fórmula general I, en donde X, Y, n, p, q y R1-R17 tienen diversos significados, para su uso en el tratamiento de la infección por coronavirus.
CL2022002398A 2020-03-02 2022-09-02 Compuestos para su uso en el tratamiento de la infección por coronavirus CL2022002398A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16

Publications (1)

Publication Number Publication Date
CL2022002398A1 true CL2022002398A1 (es) 2023-06-30

Family

ID=74797953

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002398A CL2022002398A1 (es) 2020-03-02 2022-09-02 Compuestos para su uso en el tratamiento de la infección por coronavirus

Country Status (16)

Country Link
US (1) US20230158102A1 (es)
EP (1) EP4114436A1 (es)
JP (1) JP2023517295A (es)
KR (1) KR20220151181A (es)
CN (1) CN115666615A (es)
AU (1) AU2021232534A1 (es)
BR (1) BR112022017008A2 (es)
CA (1) CA3169791A1 (es)
CL (1) CL2022002398A1 (es)
CO (1) CO2022014115A2 (es)
IL (1) IL296066A (es)
MX (1) MX2022010922A (es)
PE (1) PE20231069A1 (es)
TW (1) TW202144380A (es)
UY (1) UY39108A (es)
WO (1) WO2021175826A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE60123232T2 (de) 2000-04-07 2007-11-08 Trustees Of The University Of Pennsylvania Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA05010064A (es) 2003-03-21 2006-05-17 Madeleine M Joullie Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
JP2023517295A (ja) 2023-04-25
PE20231069A1 (es) 2023-07-17
IL296066A (en) 2022-11-01
UY39108A (es) 2021-09-30
MX2022010922A (es) 2022-09-29
TW202144380A (zh) 2021-12-01
CO2022014115A2 (es) 2022-11-18
US20230158102A1 (en) 2023-05-25
AU2021232534A1 (en) 2022-10-06
KR20220151181A (ko) 2022-11-14
EP4114436A1 (en) 2023-01-11
CA3169791A1 (en) 2021-09-10
WO2021175826A1 (en) 2021-09-10
CN115666615A (zh) 2023-01-31
BR112022017008A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
GEP20237506B (en) Pcsk9 antagonist compounds
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
CL2008001631A1 (es) Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
EA200901236A1 (ru) Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
CO2022000481A2 (es) Inhibidores de enzimas
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
SV2008002958A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
NO20071871L (no) Fosfoindoler som HIV-inhibitorer.
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
CO2022000270A2 (es) Inhibidores de enzimas
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
UA117922C2 (uk) Насичені азотовмісні та n-ациловані гетероцикли, що посилюють дію активного антибіотика проти мікобактерій
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa